Companion Diagnostic Collaboration and Licensing Deals 2010-2024


Companion Diagnostics Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2010 to 2024

Publication date
May 2024
Number of pages
Product type
Research report
Available formats
PDF document
Report edition

Companion Diagnostic Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the companion diagnostic deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of companion diagnostic deals from 2010 to 2024.

The report provides a detailed understanding and analysis of how and why companies enter companion diagnostic deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. 

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 530 companion diagnostic deals announced since 2010 including financial terms where available including links to online deal records of actual companion diagnostic partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of companion diagnostic dealmaking. 

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in companion diagnostic dealmaking since 2010.

Chapter 3 provides an overview of the leading companion diagnostic deals since 2010. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in companion diagnostic dealmaking with a brief summary followed by a comprehensive listing of companion diagnostic deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of companion diagnostic deals signed and announced since Jan 2010, where a contract document is available in the public domain. 

Chapter 6 provides a comprehensive and detailed review of companion diagnostic partnering deals signed and announced since Jan 2010. The chapter is organized by specific companion diagnostic technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in companion diagnostic deal making since 2010.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Companion Diagnostic Collaboration and Licensing Deals provides the reader with the following key benefits:

•    Understand deal trends since 2010
•    Browse companion diagnostic collaboration and licensing deals
•    Benchmark analysis – identify market value of transactions
•    Financials terms - upfront, milestone, royalties
•    Directory of deals by company A-Z, deal type and therapy area
•    Leading deals by value
•    Most active dealmakers
•    Identify assets and deal terms for each transaction
•    Access contract documents - insights into deal structures
•    Due diligence - assess suitability of your proposed deal terms for partner companies
•    Save hundreds of hours of research time

Report scope

Companion Diagnostic Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of companion diagnostic trends and structure of deals entered into by leading biopharma companies worldwide.

Companion Diagnostic Collaboration and Licensing Deals includes:
•    Trends in companion diagnostic dealmaking in the biopharma industry
•    Directory of companion diagnostic deal records covering pharmaceutical and biotechnology
•    The leading companion diagnostic deals by value
•    Most active companion diagnostic licensing dealmakers

Companion Diagnostic Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

•    What are the precise rights granted or optioned?
•    What is actually granted by the agreement to the partner company?
•    What exclusivity is granted?
•    What is the payment structure for the deal?
•    How are sales and payments audited?
•    What is the deal term?
•    How are the key terms of the agreement defined?
•    How are IPRs handled and owned?
•    Who is responsible for commercialization?
•    Who is responsible for development, supply, and manufacture?
•    How is confidentiality and publication managed?
•    How are disputes to be resolved?
•    Under what conditions can the deal be terminated?
•    What happens when there is a change of ownership?
•    What sublicensing and subcontracting provisions have been agreed?
•    Which boilerplate clauses does the company insist upon?
•    Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
•    Which jurisdiction does the company insist upon for agreement law?

Companion Diagnostic Collaboration and Licensing Deals provides the reader with the following key benefits:

•    Understand deal trends since 2010
•    Browse companion diagnostic collaboration and licensing deals
•    Benchmark analysis – identify market value of transactions
•    Financials terms - upfront, milestone, royalties
•    Directory of deals by company A-Z, deal type and therapy area
•    Leading deals by value
•    Most active dealmakers
•    Identify assets and deal terms for each transaction
•    Access contract documents - insights into deal structures
•    Due diligence - assess suitability of your proposed deal terms for partner companies
•    Save hundreds of hours of research time

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in companion diagnostic dealmaking
2.1. Introduction
2.2. Companion diagnostic deals over the years
2.3. Most active companion diagnostic dealmakers
2.4. Companion diagnostic deals by deal type
2.5. Companion diagnostic deals by therapy area
2.6. Companion diagnostic deals by industry sector
2.7. Deal terms for companion diagnostic deals
2.7.1 Companion diagnostic deals headline values
2.7.2 Companion diagnostic deal upfront payments
2.7.3 Companion diagnostic deal milestone payments
2.7.4 Companion diagnostic royalty rates

Chapter 3 – Leading companion diagnostic deals
3.1. Introduction
3.2. Top companion diagnostic deals by value

Chapter 4 – Most active companion diagnostic dealmakers
4.1. Introduction
4.2. Most active companion diagnostic dealmakers
4.3. Most active companion diagnostic deals company profiles

Chapter 5 – Companion diagnostic contracts dealmaking directory
5.1. Introduction
5.2. Companion diagnostic contracts dealmaking directory

Chapter 6 – Companion diagnostic dealmaking by technology type

Deal directory

Deal directory – Companion diagnostic deals by company A-Z
Deal directory – Companion diagnostic deals by deal type
Deal directory – Companion diagnostic deals by therapy area

Deal type definitions

About Biopharma Research Ltd 
Current Partnering
Current Agreements
Recent report titles from Current Partnering

Table of figures

Figure 1: Companion diagnostic deals since 2010
Figure 2: Active companion diagnostic dealmaking activity – 2010 - 2024
Figure 3: Companion diagnostic deals by deal type since 2010
Figure 4: Companion diagnostic deals by therapy area since 2010
Figure 5: Companion diagnostic deals by industry sector since 2010
Figure 6: Companion diagnostic deals with a headline value
Figure 7: Companion diagnostic deals with an upfront value
Figure 8: Companion diagnostic deals with a milestone value
Figure 9: Companion diagnostic deals with a royalty rate value
Figure 10: Top companion diagnostic deals by value since 2010
Figure 11: Most active companion diagnostic dealmakers 2010 - 2024
Figure 12: Companion diagnostic deals by technology type since 2010

Pricing options

  • $3,995: single-user (encrypted file - one user/device)
  • $5,995: multi-user (encrypted file - up to 5 users/devices)
  • $9,995: company (unencrypted PDF)

Single and Multi-user license files are encrypted PDF documents. Details of how to access using Javelin3 PDF Reader will be provided at report delivery.

Company license files are not encrypted and can be accessed using a PDF Reader.

A full explanation of license type definitions can be found here.


Our guarantee


Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.


Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.


Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.


Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

2cureX, 20/20 GeneSystems, A2 Biotherapeutics, Abbisko Therapeutics, Abbott Laboratories, Abbott Molecular, Abbvie, Abcam, AccuGenomics, Achaogen, Acrivon Therapeutics, ADC Therapeutics, Adial Pharmaceuticals, Advanced Biological Laboratories, Advanced Cell Diagnostics, Advanced Nuclear Medicine Ingredients, Advaxis, Aelan Cell Technologies, AEterna Zentaris, Affymetrix, Agilent Technologies, Agios Pharmaceuticals, Akili Interactive Labs, Akoya Biosciences, Albert Einstein College of Medicine, Algeta, Allarity Therapeutics, Almac Diagnostics, Almac Group, Alphageneron Pharmaceuticals, AltheaDX, Amarantus BioSciences, Ambit Biosciences, Amgen, Amoy Diagnostics, AmpliPhi Biosciences, AmpTec, Analytics Engines, AnchorDx, Angle, AnHeart Therapeutics, Apogenix, Apollomics, ArcherDX, Ariad Pharmaceuticals, Arizona State University, ARK Diagnostics, Arno Therapeutics (inactive since 2017), Array Biopharma, Arvinas, Ashvattha Therapeutics, AssureRx Health, Astellas Pharma, Astellas Pharma US, Astex Pharmaceuticals, AstraZeneca, Astrimmune, Asuragen, Atherotech, Atlas Antibodies, Aushon BioSystems, Australian Research Council, AVEO Oncology, Avila Therapeutics, Banner Sun Health Research Institute (BSHRI), Bayer, Bayer Healthcare, BC Cancer Agency, Beckman Coulter, Becton Dickinson, BeiGene, Biocare Medical, Biocartis, Biocept, BioChain, Biodesix, Biogen, Biognosys, BioImagene, BioMarin Pharmaceutical, BioMarker Strategies, Biomedix, Biomerica, bioMerieux, Biomoda, BiomX, BioNTech, BioSkryb, Biovica, Bliss Biopharmaceutical, Blueprint Medicines, Boehringer Ingelheim, Bonnie J. Addario Lung Cancer Foundation, Bpifrance, Brenus Pharma, Bristol-Myers Squibb, Bristol-Myers Squibb Pakistan, Burning Rock, Cadila Pharmaceuticals, Calviri, Cambridge Biomedical, Canary Foundation, CANbridge Pharmaceuticals, Cancer Genetics, Cancer Research Technology, Cancer Research UK, Cancer Treatment Centers of America, Carena, Caris Life Sciences, Case Western Reserve University, Cedars-Sinai Medical Center, Celgene, Celladon, Cellgen Diagnostics, Cell Signaling Technology, Centre for Imaging Technology Commercialization, Centre National de la Recherche Scientifique, Cephalon, Cepheid, Cernostics, CHDI Foundation, Chembio Diagnostics, Chronix Biomedical, Chugai Pharmaceutical, Ci-Co Healthcare, Clarient, Clavis Pharma, Clevexel Pharma, Clinical Reference Laboratory, Cloud Pharmaceuticals, Clovis Oncology, Columbia University, Columbia University Medical Center, CombiMatrix, CompanDX, Companion Dx Reference Lab, Companion Medical, Compendia Bioscience, Corgenix Medical, Cornell University, Covance, CStone Pharmaceuticals, Cynvenio, Daiichi Sankyo, Dako, Dana-Farber Cancer Institute, David H. Murdock Research Institute, Day One Biopharmaceuticals, Debiopharm, Definiens, Denovo Biopharma, Department of Defense, DermTech, DiagnoCure, DiamiR, Diaxonhit, Dimerix Biosciences, DxS, Eisai, Eli Lilly, Emory University, Empire Genomics, Endocyte, Enlyten Medical Technologies, Enterome Bioscience, Enzo Biochem, Epic Sciences, Epigenomics, Epitomics, Epizyme, Erasmus University Medical Center, Erytech Pharma, Eureka Eurostars, Eurofins Genomics, Eurofins Scientific, European Union Regional Development Fund, Eutropics Pharmaceuticals, Evotec, Exact Sciences, Exosome Diagnostics, Ferring Pharmaceuticals, Fibrocell Science, FivepHusion, Five Prime Therapeutics, Flagship Biosciences, Flare Therapeutics, Foundation Medicine, Fox Chase Cancer Center, Freenome, Fujirebio Diagnostics, Fusion Antibodies, FYR Diagnostics, Galena Biopharma, Galmed Pharmaceuticals, GE Healthcare, Geisinger Health System, Gemini Therapeutics, Genentech, Generex Biotechnology, Geneseeq, Genetic Technologies, Genmab, Genome Diagnostics, GenomeDx, Genomeon, Genomic Health, Genomic Testing Cooperative, Genoptix, Genosity, Genzyme, German Cancer Research Center, German Federal Ministry of Education and Research, Gibson Oncology, GlaxoSmithKline Biologicals, Glythera, Golden Helix, Grail, GSK, Guardant Health, HalioDx, Halozyme Therapeutics, Health Discovery, Helix, Hengrui Therapeutics, Henlius Biotech, HiberCell, Hoffmann La Roche, Horizon, Horizon Discovery, Horizon Europe, Hospices Civils de Lyon, Hospital del Mar, HotSpot Therapeutics, HTG Molecular Diagnostics, Hybrigenics, I-mab, Icon, IDbyDNA, Idera Pharmaceuticals, Illumina, ImaginAb, Imanis Life Sciences, IMIDomics, ImmunID Technologies, ImmunoCellular Therapeutics, ImmunoGen, ImmusanT, IMPACT Therapeutics, IncellDx, Incyte, Informed Data Systems, Innovate UK, Inotrem, Inova Diagnostics, Inovio Pharmaceuticals, Inserm Transfert, Insight Genetics, InSphero, IntegraGen, Intezyne, Invivis Pharmaceuticals, InVivoScribe, Ionis Pharmaceuticals, Ipsen, Ipsogen, IRCCS, Ironwood Pharmaceuticals, IRX Therapeutics, Janssen Biotech, Janssen Pharmaceutica NV, Janssen Research & Development, Jiangsu Hengrui Medicine, Johns Hopkins University, Johnson & Johnson Innovation, Kalgene Pharmaceuticals, Kanazawa University, Kartos Therapeutics, Karyopharm Therapeutics, KineMed, Kiyatec, Kreatech, Kronos Bio, KSB Diagnostics, Lab21, Laboratory Corporation of America, Lantern Pharma, Lawson Health Research Institute, Leap Therapeutics, Lehigh Valley Health Network, Leica Biosystems, Leica Microsystems, Les Laboratoires Servier, Life Technologies, Life Technologies Corporation, Locus Biosciences, London Genetics, Loxo Oncology, Luminex, Lumiphore, LUNGevity Foundation, Luye Pharma Group, Macquarie University, Macrogenics, MapKure, Massachusetts General Hospital, Massachusetts Institute of Technology, Max Planck Institute for Infection Biology, Mayo Clinic, MD Anderson Cancer Center, MDxHealth, Med BioGene, Medco Health Solutions, Medical Prognosis Institute, Medicover, Medivation, Medx, Memorial Sloan Kettering Cancer Center, Merck and Co, Merck KGaA, Merck Serono, Merrimack Pharmaceuticals, Merus, Metamark Genetics, MetaStat, Michael J Fox Foundation, Mikrogen, Millennium, Miragen Therapeutics, Mirati Therapeutics, MolecularMD, Montefiore Medical Center, Morphotek, Multimmune, Myriad Genetics, NanoString Technologies, Natera, National Cancer Institute, National Center for Drug Screening, National Heart, Lung and Blood Institute, National Institutes of Health, Navigate BioPharma Services, Nemucore Medical Innovations, Neogenix Oncology, Neogenomics, Networking Biomedical Research Centre in Liver and Digestive Diseases (CIBEREHD), NeuroMetrix, Neuron23, Newcastle University, New Liberty Proteomics, New York University, Nicholas Conor Institute for Pediatric Cancer Research, Nihon Medi-Physics, NMI TT Pharmaservices, Nodality, North Carolina State University, Novartis, Novogene, Nuclea Biotechnologies, Nucleai, NuSirt, OcellO, Offspring Biosciences, On-Q-ity, Oncoheroes Biosciences, Oncology Venture, OncoMed Pharmaceuticals, OncXerna Therapeutics, One Way Liver Genomics (OWL), Ono Pharmaceutical, Ontario Cancer Biomarker Network, OPKO Health, Oridis Biomarkers, OrigiMed, Ortho-Clinical Diagnostics, OSE Immunotherapeutics, OSEO, OSI Pharmaceuticals, Oxford BioMedica, Oxford Gene Technology, Paradigm, PathAI, Patrys, Peking University Cancer Hospital, Penn State Hershey, PerkinElmer, Personal Genome Diagnostics, Personalis, Pfizer, Pharmacyclics, PharmaMar, Photocure ASA, Pierre Fabre, Pionyr Immunotherapeutics, Piramal Imaging, Precision for Medicine, Precision Therapeutics, Predicine, Primeradx, Profusa, Promega, Prometheus Biosciences, ProPath, Protagen, Proteomics International, Puma Biotechnology, Pure MHC, Q BioMed, QED Therapeutics, Qiagen, Quest Diagnostics, Quintiles, R-Biopharm, R-Pharm, Race Oncology, Radius Health, RedHill Biopharma, Regulus Therapeutics, Relay Therapeutics, ResearchDx, Research Institute of the Hospital Universitari Vall d'Hebron, Resolution Bioscience, Respira Health, Revive Therapeutics, Roche, Roche Diagnostics, Roche Molecular Systems, Rush University Medical Center, Saladax Biomedical, Salix Pharmaceuticals, Samsung Medical Center, Sanofi, San Raffaele Scientific Institute, Scancell, Scandion Oncology, Seattle Genetics, Seegene, Sengenics, Sentinel Oncology, Seoul National University, Serametrix, Shenzhen Chipscreen Biosciences, Shuwen Biotech, Siemens Healthcare, Siemens Healthcare Diagnostics, Singapore Radiopharmaceuticals, Singulex, Sirius Genomics, Skysong Innovations, Small Business Innovation Research, Smart Personalized Medicine, Spectrum Pharmaceuticals, Splicos, SRL, St. Jude Children's Research Hospital, Stanford University, Strata Oncology, STRATIFYER Molecular Pathology, Sunnybrook Health Sciences Centre, SuperNova Diagnostics, Syapse, Syndax Pharmaceuticals, Synthon, Sysmex, Sysmex Inostics, T-Cure Bioscience, Takeda Pharmaceutical, Tasly Pharmaceuticals, TcLand Expression, Technology Strategy Board (UK), Technology Transfer Accelerator, Telix Pharmaceuticals, Tempus, Tesaro, The Fleury Group, Theradiag, Thermo Fisher Scientific, Tocagen, Tokai Pharmaceuticals, Tolero Pharmaceuticals, Total Brain, TP Therapeutics, TRACON Pharmaceuticals, Transcenta, Transgene, Transgenomic, Translational Drug Development, TScan Therapeutics, uBiome, UCB, Unilabs, University College London, University of Arkansas, University of Bonn, University of California, San Diego, University of California Los Angeles, University of Central Florida Research Foundation, University of Colorado Denver, University of Kansas, University of Minnesota, University of Newcastle, University of North Texas Health Science Center, University of Pennsylvania, University of Pennsylvania School of Veterinary Medicine, University of Pittsburgh Cancer Institute, University of Tokyo, University of Washington, USBiomarkers, ValiRx, Van Andel Institute, Vela Diagnostics, Ventana Medical Systems, Veracyte, Verastem, Veridex, VeriSIM Life, Vertex Pharmaceuticals, Viewpoint Molecular Targeting, ViiV Healthcare, ViroMed, Virovek, Vyriad, Wake Forest University School of Medicine, WAVE Life Sciences, Whitehead Institute, WuXi NextCODE Genomics, XDx, Xencor, Xenon Pharmaceuticals, Yale University, ZAI Laboratory, Zinfandel Pharmaceuticals, Zora Biosciences

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.

We found other products you might like!